Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 28, 2015
April 24, 2020
b98b0335-f4b7-4a14-88b1-7ea4d02c7e37
Related Documents
Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry
Guidance DocumentMay 14, 2019Center for Drug Evaluation and Research
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry
Guidance DocumentApril 30, 2015Center for Drug Evaluation and Research
Non-Inferiority Clinical Trials
Guidance DocumentNovember 8, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.